Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYS6077
- Development stage
- Phase 1
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
SYS6077 is an off-the-shelf, universal therapeutic messenger RNA (mRNA) cancer vaccine developed by CSPC (through its subsidiary Beijing Kangchuanglian Biopharmaceutical Technology Research). Developed using CSPC's proprietary nano-delivery technology platform, SYS6077 encodes multiple tumor neoantigens to stimulate antigen-specific T-cell immune responses, thereby enhancing the body's ability to recognize and target tumor cells. In September 2026, the National Medical Products Administration (NMPA) of China approved clinical trials for SYS6077, and it is currently being evaluated in a Phase I clinical trial for the treatment of advanced malignant solid tumors.
- Other names
- SYS6077 InjectionSYS-6077 InjectionSYS 6077 Injection
Beyond the preview
Go deeper on SYS6077.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYS6077.